A biotechnology company in British Columbia is touting successful trial results in seeking emergency approval for a nasal spray containing nitric oxide it has developed to treat individuals who are infected with COVID-19. In a phase 2 clinical trial conducted in the UK that included 79 confirmed cases of COVID-19, SaNOtize reported a 95% reduction in viral loads 24 hours after using the spray, and 99% reduction in 72 hours. Officials with the company have suggested that using the spray soon after infection can stop the illness from spreading to the lungs, thus reducing symptoms and quickening recovery time.